JP3057207B2 - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JP3057207B2 JP3057207B2 JP3250445A JP25044591A JP3057207B2 JP 3057207 B2 JP3057207 B2 JP 3057207B2 JP 3250445 A JP3250445 A JP 3250445A JP 25044591 A JP25044591 A JP 25044591A JP 3057207 B2 JP3057207 B2 JP 3057207B2
- Authority
- JP
- Japan
- Prior art keywords
- phase
- skin
- extract
- sond
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 19
- 239000000284 extract Substances 0.000 claims description 17
- 241000208223 Anacardiaceae Species 0.000 claims description 3
- 244000147370 Sclerocarya caffra Species 0.000 claims description 3
- 235000001836 Sclerocarya caffra Nutrition 0.000 claims description 3
- HOJJMIQMZPHXHW-UHFFFAOYSA-N 2-hydroxy-4-methoxybenzaldehyde Chemical compound COC=1C=C(C(C=O)=CC1)O.OC1=C(C=O)C=CC(=C1)OC HOJJMIQMZPHXHW-UHFFFAOYSA-N 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 239000012071 phase Substances 0.000 description 44
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- WZUODJNEIXSNEU-UHFFFAOYSA-N 2-Hydroxy-4-methoxybenzaldehyde Chemical group COC1=CC=C(C=O)C(O)=C1 WZUODJNEIXSNEU-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- -1 etc. Chemical compound 0.000 description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 11
- 239000002304 perfume Substances 0.000 description 10
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 9
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 7
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000002087 whitening effect Effects 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 235000011118 potassium hydroxide Nutrition 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 206010064127 Solar lentigo Diseases 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- CCWPSKZBVMNDLT-UHFFFAOYSA-N (2-hydroxy-4-methoxyphenyl)-phenylmethanone;sodium Chemical compound [Na].OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 CCWPSKZBVMNDLT-UHFFFAOYSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N n-butyl para-hydroxybenzoate Natural products CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION
【0001】[0001]
【産業上の利用分野】本発明はスクレロカリヤ・カフラ
・ソンド(Sclerocarya caffra Sond(Anacardiaceae))
抽出物又は、その有効成分である2−ヒドロキシ4−メ
トキシベンズアルデヒド(4−メトキシサリチルアルデ
ヒド)を配合する事により,日焼け後の色素沈着,し
み,そばかす,肝斑等に優れた効果を有する皮膚外用剤
に関する。The present invention relates to Sclerocarya caffra Sond (Anacardiaceae).
By incorporating the extract or its active ingredient, 2-hydroxy-4-methoxybenzaldehyde (4-methoxysalicylaldehyde), it has excellent effects on pigmentation, spots, freckles, melasma etc. after sunburn. Agent.
【0002】[0002]
【従来の技術】皮膚のしみなどの発生機序については一
部不明な点もあるが、一般には、ホルモンの異常や日光
からの紫外線の刺激が原因となってメラニン色素が形成
され、これが皮膚内に異常沈着するものと考えられてい
る。この様なしみやあざの治療法にはメラニンの生成を
抑制する物質、例えばビタミンCを大量に投与する方
法、グルタチオン等を注射する方法あるいはコウジ酸、
L−アスコルビン酸、システインなどを軟膏、クリー
ム、ローションなどの形態にして、局所に塗布するなど
の方法がとられている。2. Description of the Related Art Although there are some unclear points about the mechanism of the occurrence of skin spots and the like, melanin pigments are generally formed due to hormonal abnormalities and stimulation of ultraviolet rays from sunlight. It is believed to be abnormally deposited within. Treatment of such spots and bruises includes substances that suppress the production of melanin, such as a method of administering a large amount of vitamin C, a method of injecting glutathione, etc., or kojic acid,
A method of applying L-ascorbic acid, cysteine, or the like in the form of an ointment, a cream, a lotion, or the like, and topically applying the composition is employed.
【0003】一般に欧米ではハイドロキノン製剤が医薬
品として用いられている。しかしこれらの化合物はハイ
ドロキノンを除いてはその効果の発現がきわめて緩慢で
あるため、美白効果が十分でない。一方ハイドロキノン
は効果は一応認められているが、感作性があるため一般
には、使用が制限されている。そこでその安全性を向上
させるため高級脂肪酸のモノエステルやアルキルモノエ
ーテルなどにする試みがなされているが、エステル類は
体内の加水分解酵素によって分解されるため必ずしも安
全とはいいがたく、又エーテル類も安全性の面で充分に
満足するものが得られていない。In general, hydroquinone preparations are used as pharmaceuticals in Europe and the United States. However, these compounds, except for hydroquinone, exhibit very slow effects, and do not have a sufficient whitening effect. On the other hand, although hydroquinone has been recognized as having an effect, its use is generally restricted due to its sensitizing properties. Attempts have been made to improve the safety of monoesters and alkyl monoethers of higher fatty acids, but esters are not always safe because they are degraded by hydrolyzing enzymes in the body. No such products have been obtained that are sufficiently satisfactory in terms of safety.
【0004】そこで本発明者らはこれらの問題を解決す
るものとして、種々の植物の抽出物が経皮的に投与され
た場合にいかなる効果を生じるか鋭意研究を重ねた結
果、従来民間療法として、絞り汁、熱水抽出物あるいは
粉末が健胃薬,便秘、鎮痛薬等として用いられてきたス
クレロカリヤ・カフラ・ソンドの抽出物を配合した皮膚
外用剤が、日焼け後の色素沈着、しみ、そばかす、肝斑
等の淡色化、美白に優れた効果を有し、さらにその有効
成分が2−ヒドロキシ−4−メトキシベンズアルデヒド
であることを見いだし、本発明を完成するに至った。In order to solve these problems, the present inventors have conducted intensive studies on the effects of various plant extracts when administered transdermally. , Juice, hot water extract or powder is used as a stomachic, constipation, analgesic, etc., an external preparation for skin containing an extract of sclerocalyca cafra sond, pigmentation after sunburn, spots, freckles, It has excellent effects on lightening and whitening of liver spots and the like, and it has been found that the active ingredient is 2-hydroxy-4-methoxybenzaldehyde, which has led to the completion of the present invention.
【0005】[0005]
【課題を解決するための手段】すなわち本発明の請求項
1は、スクレロカリヤ・カフラ・ソンド抽出物を配合す
ることを特徴とする皮膚外用剤に関する。請求項2は、
下記構造式化2で表される2−ヒドロキシ−4−メトキ
シベンズアルデヒドを配合することを特徴とする皮膚外
用剤に関する。That is, claim 1 of the present invention relates to an external preparation for skin, which is characterized by containing an extract of Sclerocharya cafra sond. Claim 2
The present invention relates to an external preparation for skin, characterized by containing 2-hydroxy-4-methoxybenzaldehyde represented by the following structural formula 2.
【0006】[0006]
【化2】 Embedded image
【0007】以下本発明の構成について詳述する。本発
明に用いられるスクレロカリヤ・カフラ・ソンド(学名
Sclerocarya caffra Sond )は、ケニヤに自生するウル
シ科植物(Anacardiaceae) である。本発明で用いられる
抽出物は、上記スクレロカリヤ・カフラ・ソンドの花と
根以外の部分、主に葉と茎をメタノール、エタノール等
のアルコール類やアセトン等の有機溶媒と共に浸漬また
は加熱還流し、濾過した後、得られる抽出液を濃縮する
ことによって得られる。抽出に用いられる溶媒は通常用
いられる溶媒なら何でも構わない。本発明に用いられる
2−ヒドロキシ4−メトキシベンズアルデヒドは上記の
ような方法で得られたスクレロカリヤ・カフラ・ソンド
抽出物をさらにシリカゲルを用いたカラムクロマトグラ
フィーに付し、ヘキサン・酢酸エチル等の溶媒にて溶出
させ、分画して得ることができるが、天然物からの抽出
物に限定されず合成品を用いてもよい。Hereinafter, the configuration of the present invention will be described in detail. Sclerokaliya Kafra Songdo (scientific name) used in the present invention
(Sclerocarya caffra Sond) is a plant belonging to the family Urushi (Anacardiaceae) native to Kenya. The extract used in the present invention is a part other than the flowers and roots of the Sclerocharya cafra sond, mainly leaves and stems are dipped or heated under reflux with an organic solvent such as alcohols such as methanol or ethanol or acetone, and filtered. After that, it is obtained by concentrating the obtained extract. The solvent used for the extraction may be any commonly used solvent. 2-Hydroxy-4-methoxybenzaldehyde used in the present invention is obtained by subjecting the extract of Sclerocharya caphra sond obtained by the method described above to column chromatography using silica gel, and adding it to a solvent such as hexane / ethyl acetate. It can be obtained by elution and fractionation, but is not limited to extracts from natural products, and synthetic products may be used.
【0008】本発明におけるスクレロカリヤ・カフラ・
ソンド抽出物の配合量は、化粧料全量中、乾燥物として
0.005 〜10重量%、好ましくは0.01〜 5重量%である。
0.005 重量%以下であると、本発明でいう効果が十分に
発揮されず好ましくない。2−ヒドロキ−4−メトキシ
ベンズアルデヒドの配合量は、化粧料全量中 0.001〜5
重量%、好ましくは0.005 〜3 重量%である。In the present invention, sclerokalya kafra
The amount of Songdo extract in the total amount of cosmetics is as dry matter
It is 0.005 to 10% by weight, preferably 0.01 to 5% by weight.
If the content is less than 0.005% by weight, the effects of the present invention cannot be sufficiently exerted, which is not preferable. The blending amount of 2-hydroxy-4-methoxybenzaldehyde is 0.001 to 5 in the total amount of the cosmetic.
%, Preferably 0.005 to 3% by weight.
【0009】本発明の皮膚外用剤は前記の必須成分に加
えて必要に応じて、本発明の効果を損なわない範囲内
で、化粧品、医薬品等に一般に用いられる各種成分、す
なわち水性成分、粉末成分、油分、界面活性剤、保湿
剤、増粘剤、防腐剤、酸化防止剤、香料、色剤、薬剤等
を配合することができる。また本発明の化粧料の剤型は
任意であり、例えば化粧水等の可溶化系、乳液、クリー
ム等の乳化系あるいはファンデーション、分散液、など
の各種剤型をとることができる。The external preparation for skin of the present invention may contain, in addition to the above-mentioned essential components, various components generally used in cosmetics, pharmaceuticals, etc., ie, aqueous components and powder components, if necessary, as long as the effects of the present invention are not impaired. , An oil, a surfactant, a humectant, a thickener, a preservative, an antioxidant, a fragrance, a coloring agent, a drug, and the like. The dosage form of the cosmetic of the present invention is arbitrary, and for example, various dosage forms such as a solubilizing system such as a lotion, an emulsifying system such as a milky lotion and a cream, or a foundation and a dispersion can be used.
【0010】[0010]
【発明の効果】本発明の皮膚外用剤は、日焼け後の色素
沈着、しみ、そばかす、肝斑等の淡色化などの特に美白
効果に優れ、安全性にも優れたものである。The external preparation for skin of the present invention is particularly excellent in whitening effect such as pigmentation after sunburn, lightening of spots, freckles, and liver spots, and also excellent in safety.
【0011】[0011]
【実施例】次に実施例によって本発明をさらに詳細に説
明する。尚、本発明はこれにより限定されるものではな
い。配合量は重量%である。実施例に先立ち、本発明の
効果試験方法及び評価方法について説明する。Next, the present invention will be described in more detail by way of examples. Note that the present invention is not limited by this. The compounding amount is% by weight. Prior to the examples, the effect test method and the evaluation method of the present invention will be described.
【0012】(1) 美白効果試験方法 夏期の太陽光に4時間(1日2時間で2日間)晒された
被験者40名の上腕内側部皮膚を対象として太陽光を晒
された日の5日後より各試料を朝夕1回ずつ4週間塗布
した。パネルを一群10名に分けて、4群とし下記に示
す処方で試験を行なった。 (アルコール相) 95% エチルアルコール 55.0 ポリオキシエチレン(25 モル) 硬化ヒマシ油エーテル 2.0 酸化防止剤・防腐剤 適量 香料 適量 薬剤 (表1記載) 1.0 (水相) グリセリン 5.0 ヘキサメタリン酸ナトリウム 適量 イオン交換水 残余 <製法>水相、アルコール相を調整後可溶化する。評価方法 使用後の淡色化効果を下記の判定基準にもとずいて判定
した。 <判定> ◎:被験者のうち著効および有効の示す割合が80%以
上の場合 ○:被験者のうち著効および有効の示す割合が50〜8
0%の場合 △:被験者のうち著効および有効の示す割合が50〜3
0%の場合 ×:被験者のうち著効および有効の示す割合が30%以
下の場合 実施例1〜6,比較例1〜2 上記試験法記載の配合組成からなる試料を調製し、表1
記載の薬剤を用いて美白効果を比較した。結果は表1に
示す。(1) Whitening Effect Test Method Five days after the sun was exposed to the inner skin of the upper arm of 40 subjects who were exposed to the sunlight in summer for 4 hours (2 hours a day for 2 days). Each sample was applied once in the morning and evening for 4 weeks. The panel was divided into 10 groups and divided into 4 groups, and the test was performed according to the following formulation. (Alcohol phase) 95% Ethyl alcohol 55.0 Polyoxyethylene (25 mol) hydrogenated castor oil ether 2.0 Antioxidant / preservatives Appropriate amount Perfume Appropriate amount Chemical (Table 1) 1.0 (Water phase) Glycerin 5.0 Sodium hexametaphosphate Appropriate amount Residue <Production method> After adjusting the aqueous phase and alcohol phase, solubilize. The lightening effect after use of the evaluation method was determined based on the following criteria. <Judgment> :: When the proportion of the test subject showing significant effect and effectiveness is 80% or more ○: The ratio of the subject showing the significant effect and effectiveness is 50 to 8
0%: △: The proportion of the test subjects showing excellent and effective was 50 to 3
0%: ×: when the proportion of significant and effective among subjects is 30% or less Examples 1 to 6, Comparative Examples 1 to 2 Samples having the composition described in the above test method were prepared, and Table 1 was prepared.
The whitening effects were compared using the indicated agents. The results are shown in Table 1.
【0013】[0013]
【表1】 ─────────────────────────────────── 薬 剤 配合量(重量%) 効 果 ─────────────────────────────────── 比較例1 無添加 − × 比較例2 ハイドロキノン 1 △ 実施例1 スクレロカリヤ カフラ ソンド抽出物 1 ○ 実施例2 スクレロカリヤ カフラ ソンド抽出物 5 ○ 実施例3 スクレロカリヤ カフラ ソンド抽出物 0.01 ○ 実施例4 2−ヒドロキシ−4− メトキシベンズアルデヒド 1 ◎ 実施例5 2−ヒドロキシ−4− メトキシベンズアルデヒド 3 ◎ 実施例6 2−ヒドロキシ−4− メトキシベンズアルデヒド 0.005 ○ ─────────────────────────────────[Table 1] 量 Formulation amount (% by weight) Effect ─ ────────────────────────────────── Comparative Example 1 No addition-× Comparative Example 2 Hydroquinone 1 △ Example 1 Sclerocharya kafura sond extract 1 ○ Example 2 Sclerocharya kafura sond extract 5 ○ Example 3 Sclerocharya kafura sond extract 0.01 ○ Example 4 2-hydroxy-4-methoxybenzaldehyde 1 ◎ Example 5 2-hydroxy-4 -Methoxybenzaldehyde 3 ◎ Example 6 2-hydroxy-4-methoxybenzaldehyde 0.005 ○ ────────────────────────────── ───
【0014】表1より明らかな様に、太陽光に晒された
後の効果は比較例に比べて実施例の方が過剰のメラニン
色素の沈着を防ぎ、色黒になることを予防することが認
められた。実施例7 クリーム ステアリン酸 5.0 ステアリルアルコール 4.0 イソプロピルミリステート 18.0 グリセリンモノステアリン酸 エステル 3.0 プロピレングリコール 10.0 スクレロカリヤ・カフラ・ソンド メタノール抽出物10.0 苛性カリ 0.2 亜硫酸水素ナトリウム 0.01 防腐剤 適量 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールとスクレ
ロカリヤ・カフラ・ソンド抽出物と苛性カリを加え溶解
し加熱して70℃に保つ( 水相)。他の成分を混合し加熱融
解して70℃に保つ( 油相) 。水相に油相を徐々に加え、
全部加え終わってからしばらくその温度に保ち反応をお
こさせる。その後ホモミキサーで均一に乳化し、よくか
きまぜながら30℃まで冷却する。実施例8 クリー
ム ステアリン酸 6.0 ソルビタンモノステアリン酸 エステル 2.0 ポリオキシエチレン(20 モル) ソルビタンモノステアリン酸エステル 1.5 プロピレングリコール 10.0 2-ヒト゛ロキシ-4-メトキシヘ゛ンス゛アルテ゛ヒト゛ 0.001 グリセリントリオクタノエート 10.0 スクワレン 5.0 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え加
熱して70℃に保つ( 水相)。他の成分を混合し加熱融解し
て70℃に保つ( 油相) 。水相に油相を加え予備乳化をお
こない、 ホモミキサーで均一に乳化した後、よくかきま
ぜながら30℃まで冷却する。実施例9 クリーム ステアリルアルコール 7.0 ステアリン酸 2.0 水添ラノリン 2.0 スクワラン 5.0 2-オクチルト゛テ゛シルアルコール 6.0 ポリオキシエチレン(25 モル) セチルアルコールエーテル 3.0 グリセリンモノステアリン酸エステル 2.0 プロピレングリコール 5.0 スクレロカリヤ・カフラ・ソンド メタノール抽出物 0.005 香料 適量 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え加
熱して70℃に保つ( 水相)。他の成分を混合し加熱融解し
て70℃に保つ( 油相) 。水相に油相を加え予備乳化をお
こない、 ホモミキサーで均一に乳化した後、よくかきま
ぜながら30℃まで冷却する。実施例10 クリーム 固形パラフィン 5.0 密ロウ 10.0 ワセリン 15.0 流動パラフィン 41.0 グリセリンモノステアリン酸エステル 2.0 ポリオキシエチレン(20 モル) ソルビタンモノラウリン酸エステル 2.0 石鹸粉末 0.1 硼砂 0.2 2-ヒト゛ロキシ-4-メトキシヘ゛ンス゛アルテ゛ヒト゛ 0.05 スクレロカリヤ・カフラ・ソンドエタノール抽出物 0.05 イオン交換水 残余 香料 適量 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 (製法)イオン交換水に石鹸粉末と硼砂を加え加熱溶解
して70℃に保つ( 水相)。他の成分を混合し加熱融解して
70℃に保つ( 油相) 。水相に油相をかきまぜながら徐々
に加え反応を行う。反応終了後ホモミキサーで均一に乳
化し、 乳化後よくかきまぜながら30℃まで冷却する。実
施例11 乳液 ステアリン酸 2.5 セチルアルコール 1.5 ワセリン 5.0 流動パラフィン 10.0 ポリオキシエチレン(10モル) モノオレイン酸エステル 2.0 ポリエチレングリコール1500 3.0 トリエタノールアミン 1.0 スクレロカリヤ・カフラ・ソンドエタノール抽出液 0.01 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 カルボキシビニルポリマー (商品名:カーボポール941) 0.05 B.F. Goodrich Chemical company 香料 適量 イオン交換水 残余 (製法) 少量のイオン交換水にカルボキシビニルポリマ
ーを溶解する( A相)。残りのイオン交換水にポリエチ
レングリコール1500とトリエタノールアミンを加え加熱
溶解して70℃に保つ (水相)。他の成分を混合し加熱融解
して70℃に保つ(油相) 。水相に油相を加え予備乳化を
行い、A相を加えホモミキサーで均一に乳化し、 乳化後
よくかきまぜながら30℃まで冷却する。実施例12
乳液 (油相部) ステアリルアルコール 1.5 スクワレン 2.0 ワセリン 2.5 脱臭液状ラノリン 1.5 月見草油 2.0 ミリスチン酸イソプロピル 5.0 グリセリンモノオレート 2.0 ポリオキシエチレン(60モル)硬化ヒマシ油 2.0 酢酸トコフェロール 0.05 エチルパラベン 0.2 ブチルパラベン 0.1 2−ヒドロキシ−4−メトキシベンズアルデヒド 10.0 香料 適量 ( 水相部) 亜硫酸水素ナトリウム 0.01 グリセリン 5.0 ヒアルロン酸ナトリウム 0.01 カルボキシビニルポリマー 0.2 (商品名:カーボポール941) B.F. Goodrich Chemical company 水酸化カリウム 0.2 精製水 残余 (製法)油相部を70℃にて溶解し、同じく水相部を70℃
にて溶解し水相部に油相部を混合し、 乳化機で乳化後熱
交換機で30℃まで冷却する。実施例13 乳液 マイクロクリスタリンワックス 1.0 密ロウ 2.0 ラノリン 20.0 流動パラフィン 10.0 スクワラン 5.0 ソルビタンセスキオレイン酸 エステル 4.0 ポリオキシエチレン( 20モル) ソルビタンモノオレイン酸エステル 1.0 プロピレングリコール 7.0 スクレロカリヤ・カフラ・ソンド アセトン抽出物 10.0 エチルパラベン 0.3 亜硫酸水素ナトリウム 0.01 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え加
熱して70℃に保つ( 水相)。他の成分を混合し加熱溶解し
て70℃に保つ(油相)。油相をかきまぜながら、これに水
相を徐々に加え、ホモミキサーで均一に乳化する。乳化
後よくかきまぜながら30℃まで冷却する。実施例14
ゼリー 95% エチルアルコール 10.0 ジプロピレングリコール 15.0 ポリオキシエチレン(50 モル) オレイルアルコールエーテル 2.0 カルボキシビニルポリマー (商品名:カーボポール940) 1.0 B.F. Goodrich Chemical company 苛性ソーダ 0.15 L−アルギニン 0.1 2−ヒドロキシ−4−メトキシベンズアルデヒド 0.005 2−ヒドロキシ−4−メトキシベンゾフェノン スルホン酸ナトリウム 0.05 メチルパラベン 0.2 エチレンジアミンテトラアセテート・3ナトリウム・2水 0.05 香料 適量 イオン交換水 残余 (製法)イオン交換水にカーボポール940 を均一に溶解
し、一方95% エタノールに2−ヒドロキシ−4−メトキ
シベンズアルデヒド、ポリオキシエチレン( 50モル) オ
レイルアルコールエーテルを溶解し、水相に添加する。
ついで、その他の成分を加えたのち苛性ソーダ、L−ア
ルギニンで中和させ増粘する。実施例15 美容
液 (A相) エタノール(95%) 10.0 ポリオキシエチレン(20) オクチルドデカノール 1.0 メチルパラベン 0.15 パントテニールエチルエーテル 0.1 スクレロカリヤ・カフラ・ソンドアセトン抽出物 0.05 (B相) 水酸化カリウム 0.1 (C相) グリセリン 5.0 ジプロピレングリコール 10.0 亜硫酸水素ナトリウム 0.03 カルボキシビニルポリマー 0.2 (商品名:カーボポール940) B.F. Goodrich Chemical company 精製水 残余 (製法)A相、C相をそれぞれ均一に溶解し、C相にA
相を加えて可溶化する。ついでB相を加えたのち充填を
行う。実施例16 パック (A相) ジプロピレングリコール 5.0 ポリオキシエチレン(60モル) 硬化ヒマシ油 5.0 (B相) 2−ヒドロキシ−4−メトキシベンズアルデヒド 1.0 オリーブ油 5.0 酢酸トコフェロール 0.2 エチルパラベン 0.2 香料 0.2 ( C相) 亜硫酸水素ナトリウム 0.03 ポリビニルアルコール 13.0 (ケン化度90、 重合度2,000) エタノール 7.0 精製水 残余 (製法) A相、B相、C相をそれぞれ均一に溶解し、A
相にB相を加えて可溶化する。ついでこれをC相に加え
たのち充填を行う。実施例17 粉末入りパック (アルコール相) 95% エタノール 10.0 プロピレングリコール 5.0 2−ヒドロキシ−4−メトキシベンズアルデヒド 9.0 スクレロカリヤ・カフラ・ソンド メタノール抽出物 1.0 香料 適量 色材 適量 (水相) 亜鉛華 25.0 カオリン 20.0 メチルパラベン 0.3 グリセリン 5.0 イオン交換水 残余 (製法)室温にて水相を均一に調整する。ついで室温に
て調整したアルコール相を添加し均一に混合する。実施
例7〜13で得られた皮膚外用剤は美白効果に優れ、皮
膚に対しても安全なものであった。As is clear from Table 1, the effect of the embodiment after exposure to sunlight can be prevented from being excessively melanin pigment deposition and preventing blackening, as compared with the comparative example. Admitted. Example 7 Cream Stearic acid 5.0 Stearyl alcohol 4.0 Isopropyl myristate 18.0 Glycerin monostearate 3.0 Propylene glycol 10.0 Sclerocalyca cafra sond methanol extract 10.0 Caustic potash 0.2 Sodium bisulfite 0.01 Preservatives Appropriate amount Perfume Appropriate amount Ion-exchange water Residue (Preparation method) Add propylene glycol, sclerocalyca cafra sond extract and caustic potash to ion-exchanged water, dissolve and heat to maintain at 70 ° C (aqueous phase). Mix the other ingredients, heat and melt, and keep at 70 ° C (oil phase). Add the oil phase gradually to the water phase,
After the addition, the temperature is maintained for a while to cause the reaction. Thereafter, the mixture is uniformly emulsified with a homomixer and cooled to 30 ° C. while stirring well. Example 8 Cream stearic acid 6.0 sorbitan monostearate 2.0 polyoxyethylene (20 mol) sorbitan monostearate 1.5 propylene glycol 10.0 2-human peroxy-4-methoxybenzene artehuman 0.001 glycerin trioctanoate 10.0 squalene 5.0 sodium bisulfite 0.01 Ethylparaben 0.3 Perfume Appropriate amount Ion-exchanged water Residue (Preparation method) Add propylene glycol to ion-exchanged water and heat to 70 ° C (aqueous phase). Mix the other ingredients, heat and melt, and keep at 70 ° C (oil phase). Add the oil phase to the water phase, pre-emulsify, homogenize with a homomixer, and cool to 30 ° C with good stirring. Example 9 Cream Stearyl Alcohol 7.0 Stearic Acid 2.0 Hydrogenated Lanolin 2.0 Squalane 5.0 2-Octyltodecyl Alcohol 6.0 Polyoxyethylene (25 mol) Cetyl Alcohol Ether 3.0 Glycerin Monostearate 2.0 Propylene Glycol 5.0 Sclerocalyca Kafra Sond Methanol Extract 0.005 Perfume Appropriate amount Sodium bisulfite 0.03 Ethyl paraben 0.3 Ion-exchanged water residue (Preparation method) Add propylene glycol to ion-exchanged water and heat to 70 ° C (aqueous phase). Mix the other ingredients, heat and melt, and keep at 70 ° C (oil phase). Add the oil phase to the water phase, pre-emulsify, homogenize with a homomixer, and cool to 30 ° C with good stirring. Example 10 Cream Solid Paraffin 5.0 Beeswax 10.0 Vaseline 15.0 Liquid Paraffin 41.0 Glycerin Monostearate 2.0 Polyoxyethylene (20 moles) Sorbitan Monolaurate 2.0 Soap Powder 0.1 Borax 0.2 2-Hetoxy-4-methoxybenzene Artificial 0.05 Sclerocalyca Kafra・ Sondo ethanol extract 0.05 Ion-exchanged water Residual perfume Appropriate amount Sodium bisulfite 0.03 Ethylparaben 0.3 (Preparation method) Add soap powder and borax to ion-exchanged water, dissolve by heating and maintain at 70 ° C (aqueous phase). Mix and melt other ingredients
Keep at 70 ° C (oil phase). The oil phase is gradually added to the aqueous phase while stirring to carry out the reaction. After the completion of the reaction, homogenize the mixture uniformly with a homomixer. After the emulsification, cool to 30 ° C while stirring well. Example 11 Emulsion Stearic Acid 2.5 Cetyl Alcohol 1.5 Vaseline 5.0 Liquid Paraffin 10.0 Polyoxyethylene (10 mol) Monooleate 2.0 Polyethylene Glycol 1500 3.0 Triethanolamine 1.0 Sclerocalyca Kafra Sondethanol Extract 0.01 0.01 Sodium Bisulfite 0.01 Ethyl Paraben 0.3 Carboxyvinyl polymer (trade name: Carbopol 941) 0.05 BF Goodrich Chemical company Perfume Appropriate amount Ion exchange water Residue (Preparation method) Dissolve the carboxyvinyl polymer in a small amount of ion exchange water (A phase). Polyethylene glycol 1500 and triethanolamine are added to the remaining ion-exchanged water, dissolved by heating, and kept at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). Add oil phase to water phase, pre-emulsify, add phase A, emulsify uniformly with homomixer, and after emulsification, cool to 30 ° C with good stirring. Example 12
Emulsion (oil phase) Stearyl alcohol 1.5 Squalene 2.0 Vaseline 2.5 Deodorized liquid lanolin 1.5 Evening primrose oil 2.0 Isopropyl myristate 5.0 Glycerin monooleate 2.0 Polyoxyethylene (60 mol) hydrogenated castor oil 2.0 Tocopherol acetate 0.05 Ethyl paraben 0.2 Butyl paraben 0.1 2- Hydroxy-4-methoxybenzaldehyde 10.0 Perfume Appropriate amount (aqueous phase) Sodium bisulfite 0.01 Glycerin 5.0 Sodium hyaluronate 0.01 Carboxyvinyl polymer 0.2 (Product name: Carbopol 941) BF Goodrich Chemical company Potassium hydroxide 0.2 Purified water Residue (Preparation method) Dissolve the oil phase at 70 ° C.
Dissolve in, mix the oil phase with the aqueous phase, emulsify with an emulsifier, and cool to 30 ° C with a heat exchanger. Example 13 Emulsion Microcrystalline Wax 1.0 Beeswax 2.0 Lanolin 20.0 Liquid Paraffin 10.0 Squalane 5.0 Sorbitan Sesquioleate 4.0 Polyoxyethylene (20 mol) Sorbitan Monooleate 1.0 Propylene Glycol 7.0 Sclerocaryca Kafra Sond Acetone Extract 10.0 Ethyl Paraben 0.3 Sodium bisulfite 0.01 Perfume Appropriate amount Ion-exchanged water Residue (Preparation method) Add propylene glycol to ion-exchanged water and heat to 70 ° C (aqueous phase). Mix and heat other components and keep at 70 ° C (oil phase). While stirring the oil phase, the aqueous phase is gradually added thereto, and the mixture is uniformly emulsified with a homomixer. After emulsification, cool to 30 ° C while stirring well. Example 14
Jelly 95% ethyl alcohol 10.0 dipropylene glycol 15.0 polyoxyethylene (50 mol) oleyl alcohol ether 2.0 carboxyvinyl polymer (trade name: Carbopol 940) 1.0 BF Goodrich Chemical company caustic soda 0.15 L-arginine 0.1 2-hydroxy-4-methoxy Benzaldehyde 0.005 2-Hydroxy-4-methoxybenzophenone sodium sulfonate 0.05 Methyl paraben 0.2 Ethylenediaminetetraacetate / Trisodium / 2 water 0.05 Perfume Appropriate amount Ion exchange water Residue (Preparation method) Carbopol 940 is uniformly dissolved in ion exchange water, while 95 % 2-Hydroxy-4-methoxybenzaldehyde and polyoxyethylene (50 mol) oleyl alcohol ether are dissolved in ethanol and added to the aqueous phase.
Then, after adding other components, the mixture is neutralized with caustic soda and L-arginine to increase the viscosity. Example 15 Essence (phase A) Ethanol (95%) 10.0 polyoxyethylene (20) octyldodecanol 1.0 methyl paraben 0.15 pantothenyl ethyl ether 0.1 sclerocalyca cafra sondacetone extract 0.05 (phase B) potassium hydroxide 0.1 ( Phase C) Glycerin 5.0 Dipropylene glycol 10.0 Sodium bisulfite 0.03 Carboxyvinyl polymer 0.2 (Product name: Carbopol 940) BF Goodrich Chemical company Purified water Residue (Production method) Dissolve A phase and C phase uniformly, and dissolve into C phase A
Add phases and solubilize. Then, after adding the phase B, filling is performed. Example 16 pack (phase A) dipropylene glycol 5.0 polyoxyethylene (60 mol) hydrogenated castor oil 5.0 (phase B) 2-hydroxy-4-methoxybenzaldehyde 1.0 olive oil 5.0 tocopherol acetate 0.2 ethyl paraben 0.2 flavor 0.2 (phase C) Sodium bisulfite 0.03 Polyvinyl alcohol 13.0 (degree of saponification 90, degree of polymerization 2,000) Ethanol 7.0 Purified water Residue (Production method) A phase, B phase, and C phase are uniformly dissolved, and A
Add phase B to phase and solubilize. Then, after adding this to the phase C, filling is performed. Example 17 Pack with Powder (Alcohol Phase) 95% Ethanol 10.0 Propylene Glycol 5.0 2-Hydroxy-4-methoxybenzaldehyde 9.0 Sclerocalyca Kafra Sond Methanol Extract 1.0 Perfume Appropriate Coloring Material Appropriate Quantity (Water Phase) Zinc Flower 25.0 Kaolin 20.0 Methylparaben 0.3 Glycerin 5.0 Ion-exchange water residue (Preparation method) Adjust the aqueous phase uniformly at room temperature. Then, the alcohol phase adjusted at room temperature is added and mixed uniformly. The skin external preparations obtained in Examples 7 to 13 were excellent in whitening effect and safe for the skin.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 植原 計一 神奈川県横浜市港北区新羽町1050番地 株式会社 資生堂研究所内 審査官 塚中 直子 (56)参考文献 特開 昭60−109544(JP,A) 特開 昭50−135236(JP,A) (58)調査した分野(Int.Cl.7,DB名) A61K 7/48 A61K 7/00 A61K 35/78 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor, Keiichi Uehara 1050, Nippa-cho, Kohoku-ku, Yokohama-shi, Kanagawa Pref. Investigator, Shiseido Research Institute, Inc. Naoko Tsukanaka (56) References JP-A-60-109544 (JP, A JP-A-50-135236 (JP, A) (58) Fields investigated (Int. Cl. 7 , DB name) A61K 7/48 A61K 7/00 A61K 35/78
Claims (2)
ンド(Sclerocarya caffra Sond(Anacardiaceae))抽出
物を配合することを特徴とする皮膚外用剤。(1) An external preparation for skin, comprising an extract of Sclerocarya caffra Sond (Anacardiaceae), a plant belonging to the family Urushiaceae.
4−メトキシベンズアルデヒド(4−メトキシサリチル
アルデヒド)を配合することを特徴とする皮膚外用剤。 【化1】 2. An external preparation for skin, comprising 2-hydroxy-4-methoxybenzaldehyde (4-methoxysalicylaldehyde) represented by the following structural formula 1. Embedded image
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3250445A JP3057207B2 (en) | 1991-09-03 | 1991-09-03 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3250445A JP3057207B2 (en) | 1991-09-03 | 1991-09-03 | External preparation for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0648929A JPH0648929A (en) | 1994-02-22 |
JP3057207B2 true JP3057207B2 (en) | 2000-06-26 |
Family
ID=17207981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3250445A Expired - Fee Related JP3057207B2 (en) | 1991-09-03 | 1991-09-03 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3057207B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766575A (en) * | 1996-06-14 | 1998-06-16 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Method and composition for skin lightening |
US8246969B2 (en) | 2001-11-16 | 2012-08-21 | Skinmedica, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
PT1443915E (en) * | 2001-11-16 | 2006-11-30 | Bioform Medical Inc | Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
WO2003092634A2 (en) * | 2002-05-06 | 2003-11-13 | Engelbrecht, Edna | Topical composition for the treatment of scar tissue |
SG10201602752XA (en) * | 2011-01-07 | 2016-05-30 | Allergan Inc | Melanin modification compositions and methods of use |
-
1991
- 1991-09-03 JP JP3250445A patent/JP3057207B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH0648929A (en) | 1994-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06199646A (en) | Skin beautifying cosmetic | |
JPH064529B2 (en) | External skin preparation | |
JP3057207B2 (en) | External preparation for skin | |
JPH0812560A (en) | Skin external preparation | |
JPH06192062A (en) | Dermal external preparation | |
JP3270219B2 (en) | External preparation for skin | |
JP3048700B2 (en) | Cosmetics | |
JP2906269B2 (en) | External preparation for skin | |
JP3109623B2 (en) | Skin whitening agent | |
JPH0543446A (en) | Beautifying and whitening skin medicine for external use | |
JP3285619B2 (en) | External preparation for skin | |
JP3150781B2 (en) | External preparation for skin | |
JPH0692833A (en) | Skin external agent | |
JP3150780B2 (en) | External preparation for skin | |
JPH05255376A (en) | 5-hydroxy-7-@(3754/24)6"-p-coumaroylglucosyl) flavonol derivative and skin external preparation containing the same | |
JPH1192331A (en) | Skin preparation for external use | |
JP3150783B2 (en) | External preparation for skin | |
JPH11171757A (en) | Preparation for external use for skin | |
JPH05255063A (en) | External preparation for skin | |
JPH0840821A (en) | Skin external agent | |
JPH07121853B2 (en) | Topical skin | |
JPH11139952A (en) | External preparation for skin for whitening | |
JPH0645532B2 (en) | External skin preparation | |
JPH03279317A (en) | External preparation of skin | |
JPH0769859A (en) | External preparation for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20000309 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |